J Bader
Verbesserte Wirksamkeit von Proteasom-Inhibitoren in der Behandlung des Nierenzellkarzinoms durch die Kombination mit den HIV-Protease-Inhibitoren Lopinavir und Nelfinavir
Abt D, Driessen C, Engeler D, Schmid H, Slaby O, Vodinska M, Silzle T, Bader J, Kraus M, Sedlarikova L, Besse A, Besse L. Verbesserte Wirksamkeit von Proteasom-Inhibitoren in der Behandlung des Nierenzellkarzinoms durch die Kombination mit den HIV-Protease-Inhibitoren Lopinavir und Nelfinavir. German Medicale Science, www.egms.de 2018
Jan 1, 2018Verbesserte Wirksamkeit von Proteasom-Inhibitoren in der Behandlung des Nierenzellkarzinoms durch die Kombination mit den HIV-Protease-Inhibitoren Lopinavir und Nelfinavir
Jan 1, 2018German Medicale Science, www.egms.de 2018
Abt Dominik, Driessen Christoph, Engeler Daniel, Schmid Hans-Peter, Slaby O, Vodinska M, Silzle T, Bader J, Kraus M, Sedlarikova L, Besse A, Besse L
Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma by combination with the human immunodeficiency virus (HIV)-protease inhibitors lopinavir or nelfinavir
Abt D, Driessen C, Engeler D, Schmid H, Slaby O, Vodinska M, Silzle T, Bader J, Kraus M, Sedlarikova L, Besse A, Besse L. Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma by combination with the human immunodeficiency virus (HIV)-protease inhibitors lopinavir or nelfinavir. BJU Int 2018; 121:600-9.
Jan 1, 2018Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma by combination with the human immunodeficiency virus (HIV)-protease inhibitors lopinavir or nelfinavir
Jan 1, 2018BJU Int 2018; 121:600-9
Abt Dominik, Driessen Christoph, Engeler Daniel, Schmid Hans-Peter, Slaby O, Vodinska M, Silzle T, Bader J, Kraus M, Sedlarikova L, Besse A, Besse L
The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways
Besse L, Kraus M, Besse A, Bader J, Silzle T, Mehrling T, Driessen C. The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways. Blood Cancer J 2017; 7:e589.
Jul 28, 2017The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways
Jul 28, 2017Blood Cancer J 2017; 7:e589
Besse Lenka, Kraus Marianne, Besse Andrej, Bader J, Silzle Tobias, Mehrling T, Driessen Christoph
Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma
Besse A, Besse L, Overkleeft H, Bader J, Kraus M, Morgan G, Weinhold N, Rasche L, Stolze S, Driessen C. Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma. Leukemia 2017; 32:391-401.
Jul 5, 2017Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma
Jul 5, 2017Leukemia 2017; 32:391-401
Besse Andrej, Besse Lenka, Overkleeft H S, Bader J, Kraus Marianne, Morgan G J, Weinhold N, Rasche L, Stolze S C, Driessen Christoph
Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma
Abt D, Kraus M, Bader J, Besse A, Schmid H, Engeler D, Driessen C, Besse L (2017). Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma. Presented at: -, -
Jan 1, 2017Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma
Jan 1, 2017-
Abt Dominik, Kraus M, Bader J, Besse A, Schmid Hans-Peter, Engeler Daniel, Driessen Christoph, Besse L
Verbesserung der Wirksamkeit von Proteasom-Inhibitoren in der Behandlung des Nierenzell-Carcinoms
Abt D, Kraus M, Bader J, Besse A, Schmid H, Engeler D, Driessen C, Besse L (2017). Verbesserung der Wirksamkeit von Proteasom-Inhibitoren in der Behandlung des Nierenzell-Carcinoms. Presented at: -, -
Jan 1, 2017Verbesserung der Wirksamkeit von Proteasom-Inhibitoren in der Behandlung des Nierenzell-Carcinoms
Jan 1, 2017-
Abt Dominik, Kraus M, Bader J, Besse A, Schmid Hans-Peter, Engeler Daniel, Driessen Christoph, Besse L
Verbesserung der Wirksamkeit von Proteasom-Inhibitoren in der Behandlung des Nierenzell-Carcinoms
Abt D, Kraus M, Bader J, Besse A, Schmid H, Engeler D, Driessen C, Besse L (2017). Verbesserung der Wirksamkeit von Proteasom-Inhibitoren in der Behandlung des Nierenzell-Carcinoms. Presented at: -, -
Jan 1, 2017Verbesserung der Wirksamkeit von Proteasom-Inhibitoren in der Behandlung des Nierenzell-Carcinoms
Jan 1, 2017-
Abt Dominik, Kraus M, Bader J, Besse A, Schmid Hans-Peter, Engeler Daniel, Driessen Christoph, Besse L
Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism
Soriano G, Florea B, Overkleeft H, den Dulk H, Everts B, Bader J, Meeuwenoord N, Besse A, Kraus M, Li N, Besse L, Driessen C. Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism. Leukemia 2016; 30:2198-2207.
Apr 27, 2016Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism
Apr 27, 2016Leukemia 2016; 30:2198-2207
Soriano G P, Florea B I, Overkleeft H S, den Dulk H, Everts B, Bader J, Meeuwenoord N, Besse A, Kraus Marianne, Li N, Besse L, Driessen Christoph
Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance
Kraus M, Bader J, Overkleeft H, Driessen C. Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance. Blood Cancer J 2013; 3:e103.
Mar 1, 2013Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance
Mar 1, 2013Blood Cancer J 2013; 3:e103
Kraus Marianne, Bader J, Overkleeft H, Driessen Christoph